The stock of Catalyst Biosciences Inc. (NASDAQ:CBIO) increased by $0.05 on Wednesday to $0.42, up 14.22 percent. The last five days have seen an average of 227,507 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$0.1025. The average number of shares traded over the last 20 days was 237,472, while the average volume over the last 50 days totaled 654,081.
CBIO stock dropped -5.03% since last month. On 08/11/23, the company’s shares reached a one-month low of $0.3200. The stock touched a high of $0.50 on 01/09/23, after rallying from a low of $0.19 in 52 weeks. The price of CBIO stock has risen by 29.41% or -$0.1025 this year, reaching a new high 4 times. Still, the stock price is down -15.14% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Catalyst Biosciences Inc. (CBIO) has a trailing price-to-earnings (P/E) ratio of 1.94. Beta for the stock is 1.05.
Company paid $0.24 per share in dividends, a decrease of -83.22% from $1.43 last year.
Financial Health
For the three months ended June 29, Catalyst Biosciences Inc.’s quick ratio was 2.00, while its current ratio was 2.00, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $4000.0 and revenue of $0.79 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CBIO’s return on assets (ROA) during the last 12 months has been 16.20%. There was a 40.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 43.10%.
Earnings Surprise
According to Catalyst Biosciences Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Catalyst Biosciences Inc.’s quarterly earnings would be -$0.07, but it ended up being -$0.07. EBITDA was -$2.54 million for the quarter. Equity owned by shareholders amounts to $37.98 million.
Technical Picture
Here’s a quick look at Catalyst Biosciences Inc.’s (CBIO) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 70.91%, suggesting the stock is Overbought, with a 92.81% historical volatility rate.
The stochastic %K and %D were 66.83% and 44.74% respectively, while the average true range (ATR) was 0.0358. Based on the 14-day stochastic reading of 87.50%, the RSI (14) reading is 64.64%. On the 9-day MACD Oscillator, the stock is at 0.0277, and the 14-day reading is at 0.0236.
Analyst Ratings
Analysts have assigned Catalyst Biosciences Inc. (CBIO) an Hold rating. CBIO is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is CBIO’s price target for the next 12 months?
The current consensus forecast for the stock is between $3.00 and $3.00, with a median target price of $3.00. In analyzing these forecasts, the average price target given by analysts for Catalyst Biosciences Inc. (CBIO) is $3.00.
